Actively Recruiting

Phase Not Applicable
Age: 1Year - 120Years
All Genders
ID06507748

A Study to Evaluate the Feasibility of a Physiologic Biomarker to Assess Pain and Other Sensory Problems Using Pupillometry in Participants With Neurofibromatosis Type 1 (NF1)

Led by National Cancer Institute (NCI) · Updated on 2026-06-05

70

Participants Needed

2

Research Sites

N/A

Total Duration

On this page

AI-Summary

What this Trial Is About

Neurofibromatosis type 1 (NF1) is a genetic disorder that causes tumors to grow along nerves in the skin, brain, and other areas. People with NF1 often experience pain and other abnormal sensations like itching, numbness, or tingling, which can interfere with daily activities. Researchers are studying the use of a device called the AlgometRx Nociometer to measure pain and sensory problems in people with NF1, aiming to find a simple and objective way to assess these symptoms across different age groups. The study involves using the AlgometRx Nociometer, a device that combines infrared video pupillometry with nerve stimulation via an electrode placed on a finger or toe. The device sends non-painful electrical signals to activate nerves while a camera records changes in the pupil. Participants may complete up to three assessments: the first and second assessments within 72 hours, and an optional third assessment between 4 weeks and 18 months later. Each assessment includes testing all four limbs, with rests between tests. Participants will attend in-person visits lasting 1 to 1.5 hours each. During these visits, they will complete health and pain questionnaires, and if undergoing blood draws for other reasons, extra samples may be collected for this study. Researchers will evaluate the feasibility, acceptability, reliability, and validity of the Neuropathy Index measured by the device, alongside safety monitoring. The total number of participants is planned to be around 70, grouped by age from 1 year and older.

CONDITIONS

Brief Title

A Study to Evaluate the Feasibility of a Physiologic Biomarker to Assess Pain and Other Sensory Problems Using Pupillometry in Participants With Neurofibromatosis Type 1 (NF1)

Who Can Participate

Age: 1Year - 120Years
All Genders

Eligibility Criteria

Eligible

You may qualify if you...

  • History of clinical or genetic diagnosis of NF1 as per the 2021 revised diagnostic criteria
  • Age 1 year or older
  • At least one finger or toe without open wounds for device application
  • Ability to understand English or Spanish
  • If under 18 years, caregiver willing to assist with study procedures and device fitting
  • Caregiver of child participant 5 years or older must understand English or Spanish
  • Caregiver of child participant 1-4 years must understand English
  • Ability and willingness of participant or guardian to sign informed consent
Not Eligible

You will not qualify if you...

  • History of eye problems that prevent pupillometry, such as pupillary reflex issues, blindness, or inability to open one eye fully
  • Chronic use of medications affecting pupil response, like atropine eye drops
  • Uncontrolled illness that could increase risk to the participant

AI-Screening

AI-Powered Screening

Complete this quick 3-step screening to check your eligibility

1
2
3
+1

Your Study Journey

Screening

Duration - 2 to 4 weeks

Participants are screened for eligibility to participate in the trial.

1 visit (in-person)

Implementation

Duration - Single assessment with additional follow-up assessments up to 18 months

Participants undergo evaluation using the AlgometRx Nociometer device and complete patient- and observer-reported outcome measures to assess pain and sensory problems.

1 baseline visit and 2 follow-up visits over 4 weeks to 18 months

Trial Site Locations

Total: 2 locations

1

Children's National Medical Center

Washington D.C., District of Columbia, United States, 20010

Actively Recruiting

2

National Institutes of Health Clinical Center

Bethesda, Maryland, United States, 20892

Actively Recruiting

Loading map...

Research Team

P

Pamela L Wolters, Ph.D.

How is the study designed?

Study Type

INTERVENTIONAL

Masking

NONE

Allocation

NA

Model

SINGLE_GROUP

Primary Purpose

DEVICE_FEASIBILITY

Number of Arms

1

Similar Trials

A Phase 2, Open-Label, Single Arm Study to Evaluate the Safe...

Neurofibromatosis Type 1

Actively Recruiting

14 locations

Development of Patient-Reported Outcome Measures Assessing T...

Neurofibromatosis Type 1

Actively Recruiting

1 location

Familial Investigations of Childhood Cancer Predisposition

Acute Leukemia

Actively Recruiting

1 location

Frequently Asked Questions

Have more questions? Get in touch with our team for quick support

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here